drugset / Trial / NCT05085834
Zinc Effect on Inflammation and Cardiovascular Risk in HIV
Phase 0
Completed
95 enrolled
University Hospitals Cleveland Medical Center
Case Western Reserve University · collabNational Center for Complementary and Integrative Health (NCCIH) · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
To study the effect of short-term zinc supplementation on improving inflammation, metabolic, and cardiovascular risk among HIV infected patients on stable anti-retroviral therapy
Timeline
- Start
- 2020-01-22
- Primary completion
- 2024-08-02
- Completion
- 2024-08-02
Outcome
Mixed primary results
registry MEDIAN Placebo: 8.60 (1.65 to 20.00) absolute change (μg/dL) NCT05085834 ↗
registry MEDIAN Zinc 90 mg: 33.50 (14.00 to 62.70) absolute change (μg/dL) NCT05085834 ↗
registry analysis (other test); Placebo vs Zinc 90 mg; p <0.01; β coefficient 0.71 (95% CI 0.43 to 0.98); linear combination of coefficients NCT05085834 ↗
registry analysis (other test); Placebo vs Zinc 90 mg; p = 0.83; β coefficient 1819.18 (95% CI -14899.37 to 18537.74); linear combination of coefficients NCT05085834 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zinc gluconate | Small molecule | 90 mg | Oral |